The frequent occurrence of multidrug resistance (MDR) conferred by the overexpression of ATP-binding cassette (ABC) transporters ABCB1 and ABCG2 in cancer cells remains a therapeutic obstacle for scientists and clinicians. Consequently, developing or identifying modulators of ABCB1 and ABCG2 that are suitable for clinical practice is of great importance. Therefore, we have explored the drug repositioning approach to identify candidate modulators of ABCB1 and ABCG2 from tyrosine kinase inhibitors with known pharmacological properties and anticancer activities. In this study, we discovered that avapritinib (BLU-285), a potent, selective, and orally bioavailable tyrosine kinase inhibitor against mutant forms of KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and ABCG2. Moreover, avapritinib restores the chemosensitivity of ABCB1- and ABCG2-overexpressing MDR cancer cells at nontoxic concentrations. These findings were further supported by results of apoptosis induction assays, ATP hydrolysis assays, and docking of avapritinib in the drug-binding pockets of ABCB1 and ABCG2. Altogether, our study highlights an additional action of avapritinib on ABC drug transporters, and a combination of avapritinib with conventional chemotherapy should be further investigated in patients with MDR tumors.
Keywords: P-glycoprotein; breast cancer resistance protein; chemoresistance; combination chemotherapy with BLU-285; modulators.
Conflict of interest statement
CONFLICT OF INTEREST
The authors declare no competing financial interest.
Dacomitinib Antagonizes Multidrug Resistance (MDR) in Cancer Cells by Inhibiting the Efflux Activity of ABCB1 and ABCG2 TransportersYF Fan et al. Cancer Lett 421, 186-198. PMID 29331420.The development of multidrug resistance (MDR) to chemotherapy remains a major challenge in the treatment of cancer. Numerous mechanisms have been recognized that cause MD …
SIS3, a Specific Inhibitor of Smad3 Reverses ABCB1- And ABCG2-mediated Multidrug Resistance in Cancer Cell LinesCP Wu et al. Cancer Lett 433, 259-272. PMID 30026175.One of the major challenges in cancer chemotherapy is the development of multidrug resistance phenomenon attributed to the overexpression of ATP-binding cassette (ABC) tr …
Human ABCB1 (P-glycoprotein) and ABCG2 Mediate Resistance to BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1CP Wu et al. Biochem Pharmacol 86 (7), 904-13. PMID 23962445.The overexpression of the serine/threonine specific Polo-like kinase 1 (Plk1) has been detected in various types of cancer, and thus has fast become an attractive therape …
ABCG2/BCRP: Specific and Nonspecific ModulatorsD Peña-Solórzano et al. Med Res Rev 37 (5), 987-1050. PMID 28005280. - ReviewMultidrug resistance (MDR) in cancer cells is the development of resistance to a variety of structurally and functionally nonrelated anticancer drugs. This phenomenon has …
Lipid Regulation of the ABCB1 and ABCG2 Multidrug TransportersC Hegedüs et al. Adv Cancer Res 125, 97-137. PMID 25640268. - ReviewThis chapter deals with the interactions of two medically important multidrug ABC transporters (MDR-ABC), ABCB1 and ABCG2, with lipid molecules. Both ABCB1 and ABCG2 are …